GlassScriptPhysician profile
Ramin Hazany
NPI 1225043185
$2,018.41
in general payments reported to CMS, 2019-2025
27 companies · $54.66 in 2025
The $54.66 reported for 2025 was less than what a typical Spinal Cord Injury Medicine provider received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $166 · 2021: $98.00 · 2022: $667 · 2023: $480 · 2024: $353 · 2025: $54.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $887.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $544.90 | 2021-2024 | Vumerity, Tysabri |
| Sk Life Science, INC. | $174.43 | 2022-2023 | |
| Emd Serono, INC. | $144.51 | 2020-2024 | |
| Abbott Laboratories | $110.60 | 2022 | |
| Livanova USA, INC. | $92.98 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Genzyme Corporation | $77.62 | 2019-2022 | |
| Argenx US, INC. | $72.90 | 2022-2023 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $69.23 | 2020-2024 | |
| Ucb, INC. | $67.05 | 2020-2024 | Briviact |
| Amgen INC. | $66.64 | 2019-2020 | |
| Tanabe Pharma America, INC. | $63.55 | 2022-2023 | |
| Amneal Pharmaceuticals LLC | $59.20 | 2019-2023 | Rytary |
| Alnylam Pharmaceuticals INC. | $55.39 | 2022-2023 | Amvuttra |
| Boston Scientific Corporation | $44.63 | 2024 | |
| Acadia Pharmaceuticals INC | $40.00 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $38.74 | 2023-2024 | Gocovri, Gocovri |
| Avanir Pharmaceuticals, INC. | $37.62 | 2019 | |
| Greenwich Biosciences, INC. | $37.52 | 2020 | |
| Mallinckrodt Hospital Products INC. | $29.03 | 2024 | Acthar |
| Neurelis, INC. | $28.13 | 2025 | Valtoco |
| Lilly USA, LLC | $26.85 | 2024 | Emgality |
| Tg Therapeutics, INC. | $26.53 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $23.87 | 2023 | Fycompa |
| Alexion Pharmaceuticals, INC. | $23.17 | 2022 | |
| Acorda Therapeutics, INC | $22.94 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.43 | 2024 | Nuedexta |
| Lundbeck LLC | $19.95 | 2024 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramin Hazany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.